Clinical Trial Update: A Multiple Ascending Dose Study With AZD9164 Given for 13 Days in Healthy Male and Female Subjects and in Patients With Chronic Obstructive Pulmonary Disease [Phase 1]

View source ↗

Summary

A multiple ascending-dose Phase 1 study of AZD9164 in healthy subjects and patients with chronic obstructive pulmonary disease has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• AZD9164

Snippet

Sponsor: AstraZeneca | Conditions: Healthy, COPD | Phase 1 | Status: TERMINATED